Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA Hillard, P. J. 2005; 34 (3): 707-?

Abstract

Appropriate management of polycystic ovary syndrome in adolescents depends on recognizing the syndrome, which can have a variety of presenting complaints and must be differentiated from other causes of hyperandrogenism, as well as not dismissed as "normal adolescence." Oral contraceptives have long been considered the first line of treatment by obstetrician/gynecologists and have many advantages in treating the aspects of PCOS that are most bothersome to teens. Because of the potential risk for cardiovascular disease, early diagnosis and management may be helpful in minimizing the risk of the early metabolic correlates of adult disease.

View details for DOI 10.1016/j.ecl.2005.04.012

View details for Web of Science ID 000231677400013

View details for PubMedID 16085167